MedImmune Cambridge

• Company Profile
• Careers @ Cambridge
• Products
  • Product Pipeline
  • Cambridge-derived Products
  • Licensed Products
  • MEDI-528
• Business Development
• Drug Development
• News And Resources
• Investor Relations
• Contact

Licensed Products

Abbott | HGSI | iCo | Dyax/ImClone | Micromet |

MedImmune's (formerly CAT's) product licensees are developing seven human monoclonal antibody drug candidates, which are at various stages of clinical development. HUMIRA® is marketed by Abbott as a treatment for rheumatoid arthritis in over 50 countries worldwide, in early rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease in several European countries and the US. It is also currently being developed for juvenile rheumatoid arthritis, chronic plaque psoriasis and ulcerative colitis. ABT-874 is being developed for psoriasis and Crohn's disease, LymphoStat-B™ for systemic lupus erythematosus, HGS-ETR1 and HGS-ETR2 for cancer, ABthrax™ for anthrax infection. Further licensed product candidates are in pre-clinical development and in discovery. Our patent licensees are developing a further three human monoclonal antibody drug candidates, MT201 for carcinomas and IMC-11F8 and IMC-1121B for cancer.